2.1.2 Inclusion Criteria (Expansion P hase Only) The following inclusion criteria apply specifically to patients being considered for the expansion phase of the protocol, as described in Section 8. 29 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 2.1.2.1 Subjects with EGFR -mutated lung cancer may continue erlotinib if they have been on the drug f or ≥ 3 months with stable disease or a response. Erlotinib may also be continued in the case of a progressing tumor after prior response (or > 6 months stable disease). 2.1.2.2 Patients with ER+ breast cancer being treated with hormonal therapy (selective estrogen receptor modulator or aromatase inhibitor) who have rising tumor markers as evidence of disease progression or metastatic disease on scans may continue on hormonal therapy while being treated with vaccine. 2.1.2.3 Patients with Her2+ breast cancer receiving Her2 -directed therapy (e.g. trastuzumab) may continue on that therapy when enrolling into a dose level for which safety has been established. 2.1.2.4 Subjects with mestastatic colorectal cancer may continue “maintenance” therapy with capecitabine and/or bevacizumab. 2.1.3 Exclusion Criteria 2.1.3.1 Concurrent treatment for cancer , with specific exceptions noted in inclusion criteria. 2.1.3.2 Chronic hepatitis B or C infection, because potential immune impairment caused by these disorders may diminish the effectiveness of this immunologic therapy. 2.1.3.3 Any significant disease that, in the opinion of the investigator, may impair the patient’s tolerance of study treatment. 2.1.3.4 Significant dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent. 2.1.3.5 Active autoimmune diseases requiring treatment or a history of autoimmune disease that might be stimulated by vaccine treatment.